	Application No. Applicant(s)		
Notice of Allowability	i ppinami(e)		
	09/749,778	RALHAN, RANJU	
	Examiner	Art Unit	
	Sally A Sakelaris	1634	
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED or other appropriate comn IGHTS. This application is	in this application. If not included	l Jurse THIS
 This communication is responsive to 2/10/2003. The allowed claim(s) is/are 2-7 and 15. The drawings filed on 28 December 2000 are accepted by Acknowledgment is made of a claim for foreign priority und a) ☐ All b) ☐ Some* c) ☐ None of the: Certified copies of the priority documents have Copies of the certified copies of the priority documents have 	ler 35 U.S.C. § 119(a)-(d) of been received. been received in Application	ion No	n from the
International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 5. Acknowledgment is made of a claim for domestic priority ur (a) The translation of the foreign language provisional a 6. Acknowledgment is made of a claim for domestic priority ur	pplication has been receive	ed.	
Applicant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMENT of the second o	this communication to file his application. THIS THI	a reply complying with the require REE-MONTH PERIOD IS NOT EX	ments noted KTENDABLE.
7. A SUBSTITUTE OATH OR DECLARATION must be submINFORMAL PATENT APPLICATION (PTO-152) which gives reas	itted. Note the attached Exon(s) why the oath or decla	(AMINER'S AMENDMENT or NO aration is deficient.	TICE OF
 8. CORRECTED DRAWINGS must be submitted. (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No (b) including changes required by the proposed drawing of including changes required by the attached Examiner's 	orrection filed, whi	ch has been approved by the Exa	
Identifying indicia such as the application number (see 37 CFR 1. of each sheet. The drawings should be filed as a separate paper	84(c)) should be written on t with a transmittal letter add	the drawings in the top margin (not ressed to the Official Draftsperson.	the back)
 DEPOSIT OF and/or INFORMATION about the depose attached Examiner's comment regarding REQUIREMENT FOR THE 	it of BIOLOGICAL MAT IE DEPOSIT OF BIOLOG	ERIAL must be submitted. Not ICAL MATERIAL.	e the
Attachment(s)			
 1⊠ Notice of References Cited (PTO-892) 3□ Notice of Draftperson's Patent Drawing Review (PTO-948) 5□ Information Disclosure Statements (PTO-1449), Paper No	4⊠ Intervie 6⊠ Examin	of Informal Patent Application (PTow Summary (PTO-413), Paper No er's Amendment/Comment er's Statement of Reasons for Allo	o. <u>4'03</u> .

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

Non-elected claims 1, 8, 9, 10, 11, and 12 have been cancelled, as have claims 13, 14, and 16 whose subject matter is not in condition for allowance:

It is further noted that the title has been amended to read:

--METHOD FOR DETECTING A SINGLE NUCLEOTIDE POLYMORPHISM IN P21 WAF1/CIP1 GENE AS AN INDICATOR OF RISK OF ESOPHAGEAL CANCER--

- 1. In claim 2, delete "nuclei" and insert therefore --nucleic-- in line a). as a matter of clarity.
- 2. In the abstract, delete "oesophageal" in line 2 and insert therefore --esophageal--.

Application/Control Number: 09/749,778

Art Unit: 1634

Page 3

THE FOLLOWING IS AN EXAMINER'S STATEMENT OF REASONS FOR

ALLOWANCE:

The present invention is found to be allowable subject matter as its presentation of a

method for detecting a single nucleotide polymorphism in p21 waf1/cip1 gene as an indicator of

risk of esophageal cancer represents a contribution over the prior art that lacks any such

detection method.

The closest prior art made of record is as follows:

Wang et al. teach that p21 modifies the *in vitro* senescent response seen in AT fibroblasts

and that the loss of p21 seems to contribute to tumor suppression by a mechanism that operates

via a sensitized apoptotic response(PNAS. Vol. 94, pp.14590-14595, December 1997).

Any comments considered necessary by applicant must be submitted no later than the

payment of the issue fee and, to avoid processing delays, should preferably accompany the issue

fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for

Allowance."

Any inquiry concerning this communication or earlier communication from the examiner should be directed to Sally Sakelaris whose telephone number is (703) 306-0284. The examiner

can normally be reached on Monday-Thursday from 6:00AM-5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Gary Benzion, can be reached on (703)308-1119. The fax number for the

Technology Center is (703)305-3014 or (703)305-4242.

Any inquiry of a general nature or relating to the status of this application should be

directed to Chantae Dessau whose telephone number is (703)605-1237.

Sally Sakelaris

84/23/2003

CARLA J. MYERS

DRIMARY EXAMINER